Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 16Recruiting 8Unknown 2Terminated 2Not yet recruiting 2Enrolling by invitation 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Classical hematology 2Plasma cell 1

Conditions

Venous Thromboembolism 2Venous Thrombosis 1Pulmonary Embolism 1Multiple Myeloma 1

Interventions

Cyclophosphamide 389Carboplatin 343Gemcitabine 331pembrolizumab 328Cisplatin 327Paclitaxel 294Radiotherapy 291Docetaxel 285Bevacizumab 249Rituximab 233Capecitabine 221Nivolumab 218Dexamethasone 205Fluorouracil 189fludarabine 177Oxaliplatin 177Pemetrexed 153Doxorubicin 152Irinotecan 147Etoposide 144Leucovorin 143Cytarabine 133Bortezomib 129fludarabine phosphate 128Cetuximab 126Lenalidomide 125Filgrastim 119Erlotinib Hydrochloride 119Temozolomide 111Radiosurgery 110

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Interventional × apixaban × Clear all
NCT05171049 2026-02-23

ASTER

Anthos Therapeutics, Inc.

Phase 3 Terminated
1,150 enrolled
Classical hematology

Pulmonary Embolism, Venous Thrombosis, Venous Thromboembolism

NCT04106700 2021-02-15

Prophylaxis With Apixaban in Transplant Eligible Patients With Multiple Myeloma Receiving Induction Therapy With IMiDs

Instituto de Investigacion Sanitaria La Fe

Phase 2 Terminated
60 enrolled
Classical hematologyPlasma cell

Multiple Myeloma, Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡